Skip to content
Disclosery

Crossingbridge Advisors, LLC: FVNNR position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Crossingbridge Advisors, LLC on FVNNR, newest first. How the timeline and the estimate are built.

Crossingbridge Advisors, LLC held 0 FVNNR shares at 2025-12-31 per its 13F-HR filed 2026-02-13.

the latest 13F is the newest step

  1. period ended2025-12-31
    13F 0 shares
    Change vs previous 13F -50,000 shares

    13F-HR 0001104659-26-014810 filed by Crossingbridge Advisors, LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2025-09-30
    13F 50,000 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $7,750.

    13F-HR 0001104659-25-110900 filed by Crossingbridge Advisors, LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-06-30
    13F 50,000 shares
    Change vs previous 13F 0 shares

    0.01% of the 13F portfolio, value $9,500.

    13F-HR 0001104659-25-077288 filed by Crossingbridge Advisors, LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2025-03-31
    13F 50,000 shares
    Change vs previous 13F 0 shares

    <0.01% of the 13F portfolio, value $8,128.

    13F-HR 0001104659-25-048296 filed by Crossingbridge Advisors, LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2024-12-31
    13F 50,000 shares
    Change vs previous 13F not available

    <0.01% of the 13F portfolio, value $6,255.

    13F-HR 0001104659-25-013884 filed by Crossingbridge Advisors, LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).